CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 32 enrolled
Drug / intervention
Actiwatch 2 (Philips Respironics, Murrysville, USA)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04502654
NCT04502654N/ACompleted

Postoperative Functional Recovery After Fast-track VATS Lobectomy

Rigshospitalet, Denmark·observational·Posted Aug 6, 2020·Updated Aug 16, 2021

In Brief

An observational study evaluating Actiwatch 2 (Philips Respironics, Murrysville, USA) for Lung Neoplasms and 4 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The main aim of this research is to compare the functional recovery after discharge with the preoperative physical activity as a hypothesis generating study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 6, 2020
Enrollment StartSep 15, 2020
Primary CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.9 years ago

Interventions

Actiwatch 2 (Philips Respironics, Murrysville, USA)device

Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm\* 2.3 cm\* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.